tert-butyl (2-(3-formylphenoxy)ethyl)carbamate | 179003-14-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: tert-butyl (2-(3-formylphenoxy)ethyl)carbamate
• 英文别名: tert-butyl N-[2-(3-formylphenoxy)ethyl]carbamate
• CAS: 179003-14-6
• 化学式: C₁₄H₁₉NO₄
• mdl: MFCD11926520
• 分子量: 265.309
• InChiKey: GFUFNPGFNZGMSI-UHFFFAOYSA-N

物化性质

• 沸点：
  422.6±25.0 °C(Predicted)
• 密度：
  1.121±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-(3-formylphenoxy)ethyl)carbamate 在 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 tert-butyl N-[2-(3-[[([3-[5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-amido)-1H-1,3-benzodiazol-1-yl]propyl]carbamoyl)(methyl)amino]methyl]phenoxy)ethyl]carbamate
  参考文献：
  名称：

  [EN] STING PYRAZOLE AGONISTS AND USES THEREOF
  [FR] AGONISTES PYRAZOLPYRAZOLE DE STING ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用这些化合物调节STING并治疗STING介导的疾病的方法。

  公开号：

  WO2020132566A1
• 作为产物：
  描述：

  N-Boc-溴乙胺 、 间羟基苯甲醛 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以32.3%的产率得到tert-butyl (2-(3-formylphenoxy)ethyl)carbamate
  参考文献：
  名称：

  [EN] STING PYRAZOLE AGONISTS AND USES THEREOF
  [FR] AGONISTES PYRAZOLPYRAZOLE DE STING ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用这些化合物调节STING并治疗STING介导的疾病的方法。

  公开号：

  WO2020132566A1

文献信息

• Aromatic compounds containing basic and acidic termini useful as
  申请人：The DuPont Merck Pharmaceutical Company

  公开号：US05739163A1

  公开（公告）日：1998-04-14

  This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

  本发明涉及一种新型化合物，包含酸性和碱性末端，以及包含这种化合物的制药组合物，制备这种化合物的方法以及使用这些化合物的方法，单独或与其他治疗剂联合使用，用于抑制血小板聚集，作为溶栓剂，和/或治疗血栓栓塞性疾病。
• 3-Benzylamino-β-carboline derivatives induce apoptosis through G2/M arrest in human carcinoma cells HeLa S-3
  作者：Reiko Ikeda、Toshie Iwaki、Tomoko Iida、Takasumi Okabayashi、Eishiro Nishi、Masaki Kurosawa、Norio Sakai、Takeo Konakahara

  DOI：10.1016/j.ejmech.2010.11.044

  日期：2011.2

  beta-Carboline derivatives are known as the lead compounds for anti-tumor agents. To examine an optimal structure for anti-tumor activity, we synthesized a variety of beta-carboline derivatives, possessing a variety of substituents on the nitrogen atom of the amino group of 3-amino-beta-carboline, and evaluated their anti-tumor activity for HeLa S-3 cell line. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MU) assay showed that an optimal structure for anti-tumor activity was 3-cyclohexylmethylamino (le) or 3-benzylamino-beta-carboline (le. An optimal counter anion of 2-methyl-3-benzylamino-beta-carbolinium salts was a triflate anion 2c. In addition, the introduction of a hydroxyl group on the meta-position of the benzyl group of 3-benzylamino-beta-carboline (3e) enhanced its anti-tumor activity. Hoechst 33342 staining and DNA fragmentation assay suggested that 1f, 2c and 3e induced cell death by apoptosis unlike le. Flow cytometry analysis showed that if, 2c and 3e induced cell apoptosis through arrest of the cell cycle in the G(2)/M phase. (C) 2010 Elsevier Masson SAS. All rights reserved.
• Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer
  作者：Gang Liu、Tao Yin、Hyejin Kim、Chunyong Ding、Zhuo Yu、Hong Wang、Haiying Chen、Ruping Yan、Eric A. Wold、Hao Zou、Xi Liu、Ye Ding、Qiang Shen、Jia Zhou

  DOI：10.1016/j.ejmech.2019.06.004

  日期：2019.9

  In an effort to develop novel Bax activators for breast cancer treatment, a series of diverse analogues have been designed and synthesized based on lead compound SMBA1 through several strategies, including introducing various alkylamino side chains to have a deeper access to S184 pocket, replacing carbon atoms with nitrogen, and reducing the nitro group of 9H-fluorene scaffold. Compounds 14 (CYD-2-11) and 49 (CYD-4-61) have been identified to exhibit significantly improved antiproliferative activity compared to SMBA1, with IC50 values of 3.22 mu M and 0.07 mu M against triple-negative breast cancer MDA-MB-231 and 3.81 mu M and 0.06 mu M against ER-positive breast cancer MCF-7 cell lines, respectively. Mechanism of action studies of compound 49 indicated that it can activate Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis. Further in vivo efficacy studies of compounds 14 and 49 in nude mice bearing MDA-MB-231 tumor xenografts demonstrated that these drug candidates can significantly suppress tumor growth, indicating their therapeutic potential for the treatment of breast cancer. (C) 2019 Elsevier Masson SAS. All rights reserved.
• US5739163A
  申请人：——

  公开号：US5739163A

  公开（公告）日：1998-04-14
• [EN] STING PYRAZOLE AGONISTS AND USES THEREOF<br/>[FR] AGONISTES PYRAZOLPYRAZOLE DE STING ET LEURS UTILISATIONS
  申请人：NIMBUS TITAN INC

  公开号：WO2020132566A1

  公开（公告）日：2020-06-25

  The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of STING, and the treatment of STING-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物调节STING并治疗STING介导的疾病的方法。